Gastrointestinal disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gastrointestinal disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of Orziloben (NST-6179) for Patients with Intestinal Failure-Associated Liver Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-orziloben-nst-6179-for-patients-with-intestinal-failure-associated-liver-disease/ Wed, 29 Apr 2026 15:05:58 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-orziloben-nst-6179-for-patients-with-intestinal-failure-associated-liver-disease/ This clinical trial is focused on studying a condition known as Intestinal Failure-Associated Liver Disease (IFALD). This condition affects the liver and is associated with intestinal failure, which can lead to complications in liver function. The study is testing a new treatment called Orziloben (NST-6179), which is given as an oral solution. The purpose of the study is to evaluate the safety and how well the body tolerates this treatment, as well as to understand how the drug behaves in the body over time.

The study is divided into two parts. In the first part, participants will receive multiple doses of Orziloben (NST-6179) over a period of four weeks. In the second part, the treatment will continue for twelve weeks. Throughout the study, participants will be monitored for any side effects and changes in their health. The study will also look at how the treatment affects various aspects of liver health, such as liver inflammation and fat buildup, as well as how it influences the metabolism of lipids, glucose, and bile acids.

Participants will be randomly assigned to receive either the Orziloben (NST-6179) treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study aims to provide valuable information on the potential benefits and safety of Orziloben (NST-6179) for individuals with Intestinal Failure-Associated Liver Disease.

]]> Study on the Effects and Safety of Fecal Microbiota Transplant in Children with Autism and Digestive Issues https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-fecal-microbiota-transplant-in-children-with-autism-and-digestive-issues/ Wed, 29 Apr 2026 15:04:52 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-fecal-microbiota-transplant-in-children-with-autism-and-digestive-issues/ This clinical trial is focused on children with autism spectrum disorder who also experience digestive issues like diarrhea, abdominal pain, constipation, indigestion, or reflux. The study will use a treatment called an enema transplant of fecal microbiota, which involves introducing healthy bacteria from a donor into the child’s digestive system through the rectum. This treatment is also known by the code name MaaT 033.

The purpose of the study is to evaluate the effect and safety of this treatment in improving digestive symptoms in children with autism. The study will follow the children over a period of time to see if their digestive symptoms improve and to monitor any side effects. The treatment will be given over a maximum period of 14 days, and the children’s progress will be checked at various points, including 18 weeks after the start of the study.

Throughout the study, parents and healthcare professionals will use different questionnaires and scales to assess changes in the children’s digestive symptoms and overall well-being. The study aims to see if there is a significant reduction in digestive issues and any improvement in the core symptoms of autism. The results will help determine if this treatment could be a beneficial option for children with autism and digestive problems.

]]>